Intriguingly, mutations at ERRα’s ubiquitination sites prevented its UPS‐mediated degradation and mitigated mitochondrial damage, presenting a novel therapeutic avenue for DKD management. The gene discussed is ESRRA; the disease is diabetic kidney disease.